FindTrial
Sign In

Hepatic vein transit times of a microbubble agent in assessing response to antiviral treatment in patients with chronic hepatitis C

Hepatic vein transit times of a microbubble agent in assessing response to antiviral treatment in patients with chronic hepatitis C

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019721
Enrollment
Unknown
Registered
2018-11-25
Start date
2019-01-01
Completion date
Unknown
Last updated
2018-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis C

Interventions

Case series:antiviral therapy

Sponsors

The First Hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients with biopsy-proven HCV-related liver disease undergoing antiviral treatment from 2017 to 2020; 2. Liver contrast-enhanced ultrasonography was performed within 3 months prior to antiviral therapy.

Exclusion criteria

Exclusion criteria: 1. Other chronic liver disease patients; 2. Drink more than 20 g/day of alcohol; 3. Intravenous drug administration or administration affects hemodynamic drugs in patients; 4. Cirrhosis decompensated and liver occupying patients; 5. SonoVue allergy; 6. A woman who is pregnant or breast-feeding.

Design outcomes

Primary

MeasureTime frame
Hepatic Vein Transit Time;—

Countries

China

Contacts

Public ContactZhang Dezhi

The First Hospital of Jilin University

zhangdezhi1982@163.com+86 13504402447

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026